Despite these caveats, this study provides valuable insights into the current landscape of HER2+ breast cancer management and sets the foundation for further research and prospective validation to address these limitations and strengthen the evidence base for personalized treatment strategies. This evidence concerns the gene ERBB2 and breast carcinoma.